A microfluidics-based GBM-on-a-chip system has also been explored for the evaluation of the heterogeneity of immunosuppressive tumor microenvironments and optimization of immunotherapy targeted against the PD-1 checkpoint for different GBM subtypes. The gene discussed is RPL17; the disease is glioblastoma.